Compare Becton Dickinson and Co (BDX) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Intuitive Surgical, Inc. — how do they compare? Becton Dickinson and Co trades at $156.38 (market cap $41.51B), while Intuitive Surgical, Inc. trades at $392.63 (market cap $134.40B). The key difference: Intuitive Surgical, Inc. is far larger — about 3.2× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| BDX | ISRG | |
|---|---|---|
Market Cap | $41.51B | $134.40B |
Sector | Health | Health |
52-Week High | $185.39 | $592.85 |
52-Week Low | $135.49 | $379.50 |
Enterprise Value | $57.97B | $129.89B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Intuitive Surgical (ISRG) trades at $407.12, showing minimal daily change. The stock is in a bearish technical trend but maintains strong fundamentals with consistent revenue growth, expanding profit margins, and a history of earnings beats. Recent news highlights near-term headwinds and a significant decline from 52-week highs, yet analyst sentiment remains largely positive, focusing on long-term robotic surgery market penetration.
The outlook balances strong fundamentals against technical weakness. Investment opportunity lies in market leadership and earnings growth potential, but risks include competitive pressures and execution challenges. Wall Street consensus is bullish with a $557.60 price target, suggesting substantial upside if the company navigates current challenges successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
